Trend analysis: Alternative proteins — where the value pools are (and who captures them)

The global alternative protein market generated $17.4 billion in revenue in 2025, yet fewer than 15% of companies in the sector have achieved sustained profitability, according to the Good Food Institute's 2025 State of the Industry report. This disparity between market size and value capture reveals a sector where capital flows freely but returns concentrate narrowly. For engineers, investors, and operators evaluating opportunities in alternative proteins, understanding where value pools actually form and who captures them is the difference between participating in a growth story and underwriting someone else's losses.

Why It Matters

The alternative protein sector sits at the intersection of three converging pressures: climate regulation, food security, and shifting consumer preferences. Animal agriculture accounts for 14.5% of global greenhouse gas emissions according to the Food and Agriculture Organization, and demand for protein is projected to increase 50% by 2050 as global population approaches 10 billion. The European Union's Farm to Fork Strategy targets a 50% reduction in antimicrobial use in livestock by 2030, while the EU Green Deal's methane reduction targets directly constrain conventional animal protein production capacity.

Europe has become the regulatory epicenter of the alternative protein transition. The European Food Safety Authority (EFSA) approved Tenebrio molitor (yellow mealworm) as a novel food in 2021, opening regulatory pathways for insect protein, and has since processed applications for precision fermentation-derived ingredients at accelerating pace. The UK's National Food Strategy recommended a 30% reduction in meat consumption by 2030, backed by public procurement targets. Germany, the Netherlands, and Denmark have each announced dedicated funding programs for alternative protein R&D totaling over EUR 400 million combined between 2024 and 2028.

The market dynamics are equally compelling. McKinsey projects the alternative protein market to reach $290 billion by 2035, representing 11% of total protein consumption. BloombergNEF estimates that plant-based meat alone could capture 5% of the global meat market by 2030. Yet within these projections, value distribution is highly uneven. Ingredient suppliers and technology platform providers capture disproportionate margins while branded consumer product companies face intense competition and compressed margins. Understanding this value chain architecture is essential for any participant seeking durable competitive advantage.

Key Concepts

Plant-Based Proteins represent the most mature alternative protein category, using extraction and processing of proteins from soy, pea, wheat, fava bean, and other crops to create meat, dairy, and egg analogs. The segment reached $10.1 billion in global retail sales in 2025. Value chain stages include crop cultivation, protein isolation and texturization, formulation, and branded consumer products. The critical insight is that texturization technology and ingredient supply represent higher-margin positions than consumer product manufacturing, where brand proliferation has compressed margins to 2-5% at retail.

Precision Fermentation uses genetically engineered microorganisms (yeast, bacteria, or fungi) to produce specific proteins identical to those found in animal products, including whey, casein, collagen, and heme. The technology enables molecular-level replication without animal inputs. Production costs have declined approximately 70% since 2020 but remain 3-8x higher than conventional equivalents at scale. Value concentrates in strain engineering, bioprocess optimization, and regulatory dossier ownership.

Cultivated Meat grows animal cells in bioreactors to produce meat without slaughter. The category has attracted $3.1 billion in cumulative investment through 2025 but remains pre-commercial at meaningful scale. Singapore approved Eat Just's cultivated chicken for sale in 2020, and the US FDA and USDA granted approvals to Upside Foods and Good Meat in 2023. European regulatory approval timelines extend to 2027-2028 under EFSA's novel food framework. Value pools center on cell line development, growth media cost reduction, and bioreactor engineering.

Mycoprotein and Biomass Fermentation uses the natural growth of microorganisms to produce protein-rich biomass, exemplified by Quorn's Fusarium venenatum-based products. Unlike precision fermentation, biomass fermentation produces whole-organism biomass rather than specific isolated proteins. The category benefits from simpler regulatory pathways (classified as traditional fermentation rather than novel food in many jurisdictions) and lower production complexity.

Hybrid Products combine alternative protein ingredients with conventional animal products (e.g., blended burgers with 30-50% plant protein) to improve nutritional profiles and reduce environmental impact while maintaining familiar taste and texture. This category represents a pragmatic middle ground that captures mainstream consumers resistant to fully plant-based products.

Alternative Protein Value Chain Economics

Value Chain Position	Gross Margin Range	Capital Intensity	Competitive Moat	Value Capture Rating
Crop Breeding and Genetics	40-60%	Medium	High (IP, regulatory)	Strong
Ingredient Processing and Isolation	25-40%	High	Medium (scale, quality)	Moderate-Strong
Texturization Technology	30-50%	Medium-High	High (IP, know-how)	Strong
Strain Engineering (Fermentation)	50-70%	Low-Medium	Very High (IP, data)	Very Strong
Bioreactor and Process Equipment	20-35%	Medium	Medium (engineering)	Moderate
Consumer Product Manufacturing	5-15%	Medium	Low (brand dependent)	Weak-Moderate
Branded Retail Products	2-8%	Low-Medium	Low-Medium (brand, distribution)	Weak
Food Service and Institutional	10-20%	Low	Medium (contracts, scale)	Moderate
Regulatory and IP Services	45-65%	Low	High (expertise)	Strong

What's Working

Ingredient Platform Companies Capturing Outsized Value

The clearest value capture pattern in alternative proteins is the dominance of ingredient and technology platform companies over consumer-facing brands. Ingredion, a global ingredient solutions company, reported 2024 revenues of $7.9 billion with plant-based protein ingredients growing at 18% annually and gross margins of 28-32%. Roquette, the French ingredient company, invested EUR 600 million in the world's largest pea protein facility in Portage la Prairie, Canada, achieving 80% capacity utilization within 18 months. These companies sell to dozens of consumer brands simultaneously, diversifying customer risk while capturing the value of processing expertise and scale economics.

The pattern echoes the semiconductor industry's foundry model: TSMC captures more value than most chip designers. Similarly, Bunge and ADM have expanded plant protein processing capacity, supplying ingredients to hundreds of downstream product makers. ADM's plant protein revenues exceeded $1.2 billion in 2025, with margins substantially above its commodity grain trading business.

Precision Fermentation Economics Improving Rapidly

Perfect Day, the Berkeley-based precision fermentation company, demonstrated that fermentation-derived whey protein can reach cost parity with conventional whey in specific applications. Their partnership with Mars to incorporate animal-free whey into mainstream confectionery products validated the commercial model. The company's B2B ingredient strategy bypassed the brand-building challenge entirely, licensing technology and selling ingredients to established food manufacturers.

In Europe, Formo (Berlin) raised EUR 61 million in Series B funding in 2024 to scale precision fermentation-derived cheese proteins. Their approach targets the EUR 100 billion European cheese market, where regulatory approval via EFSA's novel food pathway is expected by 2027. The company's value capture strategy centers on owning proprietary microbial strains and fermentation protocols rather than competing in branded consumer products.

Institutional and Food Service Channels Outperforming Retail

Alternative protein companies selling through institutional channels (universities, hospitals, corporate cafeterias, and government procurement) consistently achieve higher margins and more predictable revenues than retail-focused competitors. Quorn, the UK mycoprotein company owned by Monde Nissin, reported that its food service segment grew 24% in 2024 versus 6% in retail, with food service margins approximately double retail margins. Institutional buyers prioritize consistency, nutritional specifications, and sustainability credentials over brand marketing, aligning with alternative protein companies' core competencies.

What's Not Working

Direct-to-Consumer Brand Proliferation and Margin Compression

The alternative protein retail segment has experienced severe brand proliferation. In the US alone, over 1,200 plant-based meat and dairy products competed for shelf space in 2025, according to SPINS retail data. Beyond Meat's gross margins declined from 33.7% in 2020 to approximately 5% in 2024 as price competition intensified and retailer private-label alternatives emerged. Oatly reported negative operating margins through 2025 despite strong revenue growth, illustrating the challenge of converting brand awareness into profitability in a crowded market.

European markets show similar dynamics. Retail shelf space for plant-based products in major European grocers contracted by 8-12% between 2023 and 2025 as retailers rationalized underperforming SKUs. The lesson is stark: in consumer packaged goods with low switching costs, brand alone is insufficient to sustain premium pricing once competition scales.

Cultivated Meat Cost Barriers Persisting

Despite significant investment, cultivated meat production costs remain prohibitively high for commercial scale. Independent techno-economic analyses estimate current costs at $30-80 per kilogram at pilot scale, compared to $3-5 per kilogram for conventional chicken. Growth media, which constitutes 55-80% of production cost, requires further breakthroughs in recombinant growth factor production and serum-free formulations. The CE Delft report commissioned by the Good Food Institute projected that even optimistic scenarios do not achieve cost parity with conventional meat before 2035.

Regulatory timelines compound the challenge. EFSA's novel food approval process requires comprehensive safety dossiers including allergenicity testing, nutritional analysis, and toxicological evaluation, typically requiring 18-30 months from submission to decision. As of early 2026, no cultivated meat product has received EFSA approval.

Consumer Acceptance Plateaus in Key Markets

After years of rapid growth, plant-based meat sales plateaued in several mature markets. US plant-based meat retail sales declined 1.2% in 2024 after a 4% decline in 2023, according to the Plant Based Foods Association. Consumer research by Deloitte found that taste, texture, and price remain the primary barriers, with 62% of consumers who tried plant-based meat citing taste dissatisfaction as their reason for not repurchasing. Ultra-processed food concerns have also emerged as a headwind, with health-conscious consumers questioning ingredient lists on alternative protein products.

Key Players

Established Leaders

DSM-Firmenich operates one of the world's largest plant protein and fermentation ingredient businesses, supplying foundational ingredients to hundreds of alternative protein brands across Europe and globally.

Ingredion provides texture and protein solutions with plant-based protein revenues growing at 18% annually, serving as a critical infrastructure layer for the alternative protein value chain.

Quorn Foods (Monde Nissin) remains the global leader in mycoprotein, with over 40 years of commercial-scale biomass fermentation experience and a presence in 18 countries.

Emerging Startups

Formo (Berlin) is developing precision fermentation-derived cheese proteins targeting the European market, with EFSA novel food application in progress and EUR 61 million in Series B capital.

Meati Foods (Boulder, Colorado) produces whole-cut meat alternatives from mycelium using proprietary biomass fermentation, achieving whole-food positioning that avoids ultra-processed food criticism.

Solar Foods (Helsinki) produces Solein protein from CO2, water, and electricity via gas fermentation, with production costs declining 60% since its 2024 factory launch in Vantaa, Finland.

Key Investors and Funders

Temasek has deployed over $500 million into alternative proteins globally, with significant allocations to precision fermentation and cultivated meat companies.

Blue Horizon (Zurich) manages over $900 million focused exclusively on alternative protein and sustainable food system investments across the value chain.

European Innovation Council (EIC) has allocated EUR 300 million in grants and equity investments for novel food technologies, including alternative protein scale-up projects.

Action Checklist

• Map the value chain position of your company or target investment, prioritizing ingredient and technology platform layers over consumer brand positions
• Evaluate regulatory pathway timelines in target markets, particularly EFSA novel food requirements for fermentation-derived products
• Assess production cost trajectories against conventional protein benchmarks, requiring independent techno-economic analysis rather than vendor projections
• Prioritize food service and institutional channels for initial market entry, where margins and contract stability exceed retail
• Develop IP strategy around processing technology, strain libraries, or formulation expertise rather than brand alone
• Analyze consumer acceptance data in target demographics, including repeat purchase rates and willingness to pay premiums
• Build partnerships with established ingredient companies to access processing infrastructure and distribution networks
• Monitor hybrid product opportunities combining alternative and conventional proteins for mainstream consumer appeal

FAQ

Q: Where is the most durable value in the alternative protein value chain? A: Value concentrates in technology and ingredient platform positions. Strain engineering for precision fermentation (50-70% gross margins), crop genetics for optimized protein crops (40-60% margins), and texturization technology licensing (30-50% margins) consistently outperform consumer-facing brand positions (2-8% retail margins). The pattern mirrors other technology-driven industries where platform and infrastructure layers capture disproportionate returns.

Q: Is plant-based meat growth really stalling, or is this a temporary correction? A: The data suggests a structural correction rather than a temporary pause. US and European retail sales of plant-based meat have declined or plateaued for two consecutive years. However, this masks growth in other categories: plant-based dairy (particularly milk) continues to grow at 7-10% annually, and precision fermentation-derived ingredients are growing at 25-35% annually. The sector is not stalling but restructuring around products with genuine taste and price parity rather than novelty-driven trial purchases.

Q: What are the realistic timelines for cultivated meat commercialization in Europe? A: EFSA novel food approval for cultivated meat products is unlikely before 2028 at the earliest. Post-approval, commercial-scale production facilities require 2-3 years to build and commission. Cost-competitive production at scale is projected for the mid-2030s. Engineers and investors should plan accordingly, with nearer-term returns available in precision fermentation and plant-based ingredient innovations that use established regulatory pathways.

Q: How should European companies position against US and Asian competitors? A: Europe's competitive advantages lie in regulatory rigor (EFSA approval creates a significant barrier to entry), precision fermentation expertise (Europe has strong capabilities in industrial biotechnology), and institutional market access (European public procurement programs increasingly mandate sustainable food sourcing). European companies should leverage these structural advantages rather than competing on consumer brand marketing, where US companies have stronger distribution infrastructure and lower customer acquisition costs.

Sources

• Good Food Institute. (2025). State of the Industry Report: Alternative Proteins 2025. Washington, DC: GFI.
• BloombergNEF. (2025). Plant-Based and Cultivated Protein Outlook: Market Sizing and Investment Trends. New York: Bloomberg LP.
• McKinsey & Company. (2025). Alternative Proteins: The State of Play Across the Value Chain. McKinsey Global Institute.
• CE Delft. (2024). Techno-Economic Assessment of Cultivated Meat: Cost Projections to 2040. Delft, Netherlands: CE Delft.
• European Commission. (2025). Farm to Fork Strategy: Progress Report and Updated Targets. Brussels: European Commission.
• Plant Based Foods Association. (2025). US Retail Market Data: Plant-Based Foods Sales and Trends. Washington, DC: PBFA.
• Food and Agriculture Organization of the United Nations. (2024). Livestock's Long Shadow: Updated Environmental Assessment. Rome: FAO.